The World Health Organization (WHO) has recommended a trial of the Ervebo vaccine in the Democratic Republic of the Congo (DRC) as the country reports over 4,000 confirmed Ebola cases. The recommendation comes after preliminary findings from animal studies suggested that Ervebo could offer some cross-protection against the Bundibugyo virus, which is responsible for the current outbreak (eastleighvoice.co.ke).
The Bundibugyo epidemic, now the world’s second-largest, has been described as the fastest-spreading on record. Health officials warn that the outbreak continues to expand, with new cases reported regularly in several provinces. The WHO’s call for a vaccine trial marks a significant step in the global effort to contain the virus and prevent further spread (aljazeera.com).
Ervebo, developed by the pharmaceutical company Bavarian Nordic, is already approved for use against the Zaire ebolavirus. The cross-protection hypothesis is based on research showing that the vaccine may also be effective against other strains of the Ebola virus. Scientists are now working to determine whether this potential benefit can be applied in the current outbreak.
The DRC has faced multiple Ebola outbreaks in recent years, highlighting the ongoing challenge of controlling the disease in regions with limited healthcare infrastructure. The WHO’s recommendation underscores the urgency of finding an effective response to the current crisis.
